{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:38:35Z","timestamp":1772689115463,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R01DA03546"],"award-info":[{"award-number":["R01DA03546"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.drugalcdep.2019.107688","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T12:28:28Z","timestamp":1572265708000},"page":"107688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Individual differences in human opioid abuse potential as observed in a human laboratory study"],"prefix":"10.1016","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3746-3108","authenticated-orcid":false,"given":"Kelly E.","family":"Dunn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7443-3237","authenticated-orcid":false,"given":"Frederick S.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna","family":"Brands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1755-6481","authenticated-orcid":false,"given":"David C.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George E.","family":"Bigelow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.drugalcdep.2019.107688_bib0005","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans. Automat. Contr."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.drugalcdep.2013.01.001","article-title":"Opioid abusers\u2019 ability to differentiate an opioid from placebo in laboratory challenge testing","volume":"132","author":"Antoine","year":"2013","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.drugalcdep.2019.107688_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0020","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0022-3565(25)21053-9","article-title":"Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect","volume":"251","author":"Bickel","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0022-3565(25)24264-1","article-title":"Acute physical dependence in man: effects of naloxone after brief morphine exposure","volume":"244","author":"Bickel","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1399-0004.2012.01923.x","article-title":"Opioid genetics: the key to personalized pain control?","volume":"82","author":"Branford","year":"2012","journal-title":"Clin. Genet."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0035","first-page":"187","article-title":"Observational study to calculate addictive risk to opioids: a validation study of a predictive algorithm to evaluate opioid use disorder","volume":"10","author":"Brenton","year":"2017","journal-title":"Pharmgenomics Pers. Med."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1360-0443.1998.931738.x","article-title":"A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction","volume":"93","author":"Brewer","year":"1998","journal-title":"Addiction"},{"issue":"Suppl 1","key":"10.1016\/j.drugalcdep.2019.107688_bib0045","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.drugalcdep.2009.04.003","article-title":"Principles of laboratory assessment of drug abuse liability and implications for clinical development","volume":"105","author":"Carter","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0050","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.pain.2012.07.035","article-title":"Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations","volume":"153","author":"Comer","year":"2012","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.drugalcdep.2019.107688_bib0055","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00213-017-4814-3","article-title":"Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study","volume":"235","author":"Dunn","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0060","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1176\/ps.50.6.813","article-title":"Predicting outcome of inpatient detoxification of substance abusers","volume":"50","author":"Franken","year":"1999","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0065","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1046\/j.1360-0443.2002.00227.x","article-title":"Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effect of coping responses","volume":"97","author":"Gossop","year":"2002","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0070","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0091-3057(90)90421-D","article-title":"Acute opioid physical dependence in humans: effect of naloxone at 6 and 24 hours postmorphine","volume":"36","author":"Heishman","year":"1990","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0075","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0022-3565(25)22236-4","article-title":"Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I","volume":"250","author":"Heishman","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bja.2018.03.009","article-title":"Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis","author":"Higgins","year":"2018","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/09540261.2018.1514295","article-title":"Systematic review of sex-based differences in opioid-based effects","volume":"30","author":"Huhn","year":"2018","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0090","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0304-3959(83)90018-0","article-title":"Sources of variation in analgesic responses in cancer patients with chronic pain receiving morphine","volume":"15","author":"Kaiko","year":"1983","journal-title":"Pain"},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0095","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0022-3565(25)23151-2","article-title":"Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval II","volume":"255","author":"Kirby","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1744-8069-9-45","article-title":"Sex differences in opioid analgesia and addiction: interactions among opioid receptors and estrogen receptors","volume":"9","author":"Lee","year":"2013","journal-title":"Mol. Pain"},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0105","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1373\/clinchem.2016.264986","article-title":"Analgesia and opioids: a pharmacogenetics shortlist for implementation in clinical practice","volume":"63","author":"Matic","year":"2017","journal-title":"Clin. Chem."},{"issue":"Suppl 1","key":"10.1016\/j.drugalcdep.2019.107688_bib0110","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.drugalcdep.2006.01.015","article-title":"Research design strategies to evaluate the impact of formulations on abuse liability","volume":"83","author":"McColl","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0115","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1037\/0022-006X.62.6.1141","article-title":"Similarity of outcome predictors across opiate, cocaine, and alcohol treatments: role of treatment services","volume":"62","author":"McLellan","year":"1994","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0376-8716(98)00176-8","article-title":"Identifying methadone maintenance clients at risk for poor treatment response: pretreatment and early progress indicators","volume":"55","author":"Morral","year":"1999","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(90)90025-9","article-title":"The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions","volume":"43","author":"Portenoy","year":"1990","journal-title":"Pain"},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0130","series-title":"R: a Language and Environment for Statistical Computing","author":"R Core Team","year":"2018"},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0135","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/10550490902927785","article-title":"Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence","volume":"18","author":"Raby","year":"2009","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0140","series-title":"Hierarchical Linear Models. Applications and Data Analysis Methods","author":"Raudenbush","year":"2002"},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0145","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.clpt.6100492","article-title":"Assessing abuse liability during drug development: changing standards and expectations","volume":"83","author":"Schoedel","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.drugalcdep.2019.107688_bib0150","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1214\/aos\/1176344136","article-title":"Estimating the dimension of a model","volume":"6","author":"Schwarz","year":"1978","journal-title":"Ann. Stat."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0155","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.sjpain.2017.09.009","article-title":"Individual variability in clinical effect and tolerability of opioid analgesics\u2013Importance of drug interactions and pharmacogenetics","volume":"17","author":"Solhaug","year":"2017","journal-title":"Scand. J. Pain"},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0160","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0022-3565(25)11174-9","article-title":"Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers","volume":"261","author":"Strain","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0165","series-title":"Assessment of Abuse Potential of Drugs: Guidance for Industry","author":"US Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0170","series-title":"The Abuse Potential of Prescription Opioids in Humans\u2014Closing in on the First Century of Research","first-page":"33","author":"Walsh","year":"2016"},{"key":"10.1016\/j.drugalcdep.2019.107688_bib0175","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0022-3565(25)21159-4","article-title":"Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans","volume":"279","author":"Walsh","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037687161930465X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037687161930465X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:07:24Z","timestamp":1759828044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037687161930465X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":35,"alternative-id":["S037687161930465X"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107688","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individual differences in human opioid abuse potential as observed in a human laboratory study","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107688"}}